IPO Details
Bidding Dates
15 May 24 - 17 May 24
Price Range ₹
93 - 97
Total Equity
₹ 43.17Cr
Lot Size
1200
Exchange Status
NSE
IPO Doc
Subscription Rate
Non-Institutional Investor
0.00×
Qualified Institutional Buyers
0.00×
Employees
0.00×
Retail Investors
0.00×
Total subscription Rate
0.00×
IPO Timeline
Offer start
15 May 2024
Offer end
17 May 2024
Allotment
21 May 2024
Refund initiation
22 May 2024
Demat transfer
22 May 2024
Listing
23 May 2024
Offer start
15 May 2024
Offer end
17 May 2024
Allotment
21 May 2024
Refund initiation
22 May 2024
Demat transfer
22 May 2024
Listing
23 May 2024
About Company
Established in June 1998, Quest Laboratories Limited is a pharmaceutical company specializing in the production of a wide range of medications, including antibiotics, antimalarial, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, and antidepressants. Operating predominantly within the domestic market, the company serves twelve states and two union territories, encompassing Uttar Pradesh, Madhya Pradesh, Maharashtra, Delhi, Jharkhand, Assam, Karnataka, Jammu & Kashmir, Rajasthan, West Bengal, Gujarat, Telangana, Haryana, and Bihar. Located in Dhar, Madhya Pradesh, the company's manufacturing unit adheres to stringent quality standards, holding WHO Schedule M GMP and GLP certifications, along with ISO/IEC 17025:2017 and ISO 9001:2015 accreditations. As of December 31st, 2023, Quest Laboratories Limited employs a workforce of 83 individuals, responsible for various facets of manufacturing operations, including production, quality control, technical and engineering support services, inventory management, administration, as well as tasks such as storage, packing, and dispatch.
Year Founded
01-06-1998
Promotor Details
Promoter Holdings Details
| Particular | Pre-IPO | Post-IPO |
|---|---|---|
| Percentage | 90.36 | 0 |
| Share Capital | 10786900 | 0 |
Offer to Public
44,50,000.00 Cr
Project Details
- Funding of capital expenditure towards purchase of plant and machineries for expansion - 260cr
- Funding Working Capital Requirements of our Company - 100cr
Objectives
- Funding of capital expenditure towards purchase of plant and machineries for expansion at the existing manufacturing facility
- Funding working capital requirements of our company
- General corporate purposes
Highlights
- Quest Laboratories Limited offers a wide range of pharmaceutical formulations, catering to various medical needs. This diversity enhances its market reach and revenue potential.
- The company generates revenue from government institutions, indicating a level of trust and recognition within the healthcare sector, potentially providing stability and consistent income streams.
- With WHO Schedule M GMP, GLP, and ISO certifications, Quest Laboratories demonstrates a commitment to maintaining high-quality standards and compliance with regulatory requirements, fostering trust among customers.
- The presence of an experienced promoter and management team contributes to effective decision-making, strategic planning, and operational efficiency, enhancing the company's overall performance.
- Quest Laboratories' efficient supply chain management enables timely delivery of products, optimizing operational costs and customer satisfaction.
Challenges
- Despite operating in 12 states and two union territories, Quest Laboratories' geographic presence might be limited compared to larger competitors, potentially restricting market reach and growth opportunities.
- The company's manufacturing of 250-300 formulations due to market trends and limited formulation lines may expose it to fluctuations in demand and revenue volatility.
- While successful government tender contracts provide revenue opportunities, reliance on such contracts also poses risks associated with contract renewal, competitive bidding, and payment delays.
- Although Quest Laboratories has FDA and equivalent body approvals for over 600 formulations, its manufacturing capacity for 250-300 types of formulations may limit scalability and ability to meet increasing demand.
- The concentration of operations in a single manufacturing facility and reliance on a relatively small workforce may pose operational risks such as production disruptions and resource constraints.
Financials
| Years | Total Assets | Share Capital | Profit After Tax | Consolidated Net Profit | Adjusted EPS |
|---|---|---|---|---|---|
| 2024 | 59,29,096.50 | 11,93,760.00 | 410.50 | 410.50 | 3.8052 |
| 2023 | 46,94,180.00 | 1,07,876.00 | 65.50 | 65.50 | 0.6072 |
| 2021 | 1,839.64 | 107.88 | 10,09,391.75 | 10,09,391.75 | 8.4556 |
| 2022 | 3,479.86 | 107.88 | 10,09,391.75 | 10,09,391.75 | 8.4556 |
